Clinical Trial Search

Primary: Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12 — -0.10; -0.15; -0.53 Log(mg/g) — p=0.7953

Primary: Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day. — 91; 112 participants — p=<0.05

Primary: Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12) — 0.152; -0.173…

Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and…

Primary: Changes in Urine Albumin to Creatinine Ratio (UACR) — -64.6; 104.8 mg/g — p=0.279

Primary: Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio — 256.1; 376.2 Ratio

Primary: Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 — 13.27; 5.02 percent (%)

Primary: Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria — 39; 30 Participants

Primary: Number of Participants With Macroalbuminuria After 6 Months of Treatment — 7; 6 participants

Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05

Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01

Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr

Primary: Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24 — -0.85; -0.27…

Primary: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group — 705.72; 696.30; 758.22; 705.29 mg/g — p=1.000

Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g

Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change

Primary: Progression of Albuminuria — 153.01; 99.80 Events per 1000 patient-year — p=<.0001

Primary: GFR (Glomerular Filtration Rate) Change After Treatment — 22; 1; 8; 0 ml/min/1.73m^2

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants

Primary: HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment — -0.03; -0.63 Percentage of HbA1c — p=<0.0001

Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change

Primary: Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment — 41; 16; 8; 1 Participants

Primary: Number of Participants With Decline in GFR — 2; 2; 1; 4 participants

Primary: Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid…

Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. — 1.016; 0.955; 0.874 mg/g

Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999

Primary: Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine…

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL